FGF21 and Hepatic steatosis: Qi Zhang et al found that MS-275 can induce the hepatic fibroblast growth factor 21 (FGF21) expression.[73] FGF21 can regulate lipid metabolism and improves insulin resistance, which is one of the causes of MAFLD.[74] In a phase 2 study, hepatic steatosis is decreased after 16 weeks administering pegbelfermin, a FGF21 analogue, to patients with NASH.[74] Thus, MS-275 has the huge potential to cure MAFLD and COVID-19 comorbidity patients.